Engineered extrachromosomal oncogene amplifications promote tumorigenesis. | Pradella D, Zhang M, Gao R, Yao MA, Gluchowska KM, Cendon-Florez Y, Mishra T, La Rocca G, Weigl M, Jiao Z, Nguyen HHM, Lisi M, Ozimek MM, Mastroleo C, Chen K, Grimm F, Luebeck J, Zhang S, Zolli AA, Sun EG, Dameracharla B, Zhao Z, Pritykin Y, Sigel C, Chang HY, Mischel PS, Bafna V, Antonescu CR, Ventura A | Nature. 2024 Dec 18. doi: 10.1038/s41586-024-08318-8. |
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. | Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A | Nature. 2014 Dec 18;516(7531):423-7. doi: 10.1038/nature13902. Epub 2014 Oct 22. |
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. | Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A | Nat Commun. 2017 Jul 11;8:15987. doi: 10.1038/ncomms15987. |